Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Electronic Labeling Submissions Proposed For Home-Use Devices

Executive Summary

US FDA is proposing a rule that would require manufacturers to electronically submit labeling and package inserts for class II and III devices that are intended for use outside health-care facilities. The agency is also planning a public database of the labeling.

You may also be interested in...

US FDA Shelves Proposal To Mandate Home-Use Device E-Labeling

A controversial 2016 proposed rule that would have required manufacturers of many class II and class III home-use devices to electronically submit device labeling information to US FDA will not be finalized, the agency affirmed in the Oct. 17 HHS Unified Agenda document. The agency also signaled plans to imminently finalize a broad device classification rule, and other updates.

FDA Home-Use e-Labeling Proposal Gets Serious Pushback From Medtech Firms

The US agency's proposed rule mapping out a system for requiring manufacturers of many class II and class III home-use devices to submit device labeling and packaging to FDA electronically is unnecessary and could create confusion, several industry groups argued in recent comments. In addition, several groups pointed to specific exemptions that should be made from the mandate, including mobile devices and other medtech products with embedded software.

Home-Use E-Labeling Pilot Round 2: CDRH Seeks Volunteers

FDA’s device center issued a request to participate for a pilot asking companies to electronically submit labeling for home-use devices to help develop a label database. This is the agency’s second go at such a pilot but the submissions process appears to be simplified this time around.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts